Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 6-substituted-2-([1,1?-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile.

Abstract: Disclosed are pharmaceutical combinations and methods of treating a clinical condition, e.g., AML, by administering to a subject a pharmaceutical combination comprising a DHODH inhibitor and an anti-CD38 therapeutic agent such as a anti-CD38 antibody. The pharmaceutical combination can further comprise one or more additional therapeutic agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 6-substituted-2-(phenylheteroaryl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH). The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 6-substituted-2-(phenylheteroaryl)quinoline-4-carboxylic acid analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH). The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: An expandable hunting arrowhead which ejects a signal generator and transmitter into the body of the quarry animal upon impact is described. The action of expanding blades, which rotate radially outwardly and backwardly to deploy from the sides of the arrowhead upon impact, separates the tip of the arrow containing the signal generator and transmitter in a sideways manner from the rest of the arrowhead. The sideways separation is obtained as a result of the rotating action of the blades, and the linear action of a plunger acted upon by the blades within the arrowhead. This way, the signaling tip is more likely to stay within the body of the animal, and not pass through it, to help the hunter locate the body.

Abstract: An expandable hunting arrowhead which ejects a signal generator and transmitter into the body of the quarry animal upon impact is described. The action of expanding blades, which rotate radially outwardly and backwardly to deploy from the sides of the arrowhead upon impact, separates the tip of the arrow containing the signal generator and transmitter in a sideways manner from the rest of the arrowhead. The sideways separation is obtained as a result of the rotating action of the blades, and the linear action of a plunger acted upon by the blades within the arrowhead. This way, the signaling tip is more likely to stay within the body of the animal, and not pass through it, to help the hunter locate the body.

Abstract: A dry kiln for wood products that has sample tunnels mounted strategic to each of the charges (stacks) of wood products that are to be dried. A board sample is mounted in the tunnel that is representative of the charges to be dried. A sensing device mounted in the tunnel and supporting the board sample continuously monitors the weight of the board sample and inputs the information to a controller. The moisture content of the board sample at any time during the cycle is ascertained by weight. The board sample in the tunnel is subjected to the same drying conditions as the charge and therefore the moisture content of the charge will be the same as the board sample. The continuous weight monitoring of the board sample is accordingly used by the controller to control the dry cycle.

Abstract: A weight driven kiln control system is shown and described wherein a digital scale provides sample board weight values to a kiln control system in association with sample board identification values whereby the control system may drive a load through a given drying schedule by inferring the moisture content of the load based on received weight values for a set of sample boards. The control system requires less operator expertise in manipulating the progress of the kiln through the drying schedule, and allows the kiln control system to make certain judgements about the rate of drying within the kiln and independent adjustments, if so authorized, in the drying schedule based on a calculated drying rate.

Abstract: A kiln for the drying of lumber utilizing panels attached to the kiln structure. The attached panels form the interior surface and the exterior surface of the kiln. The panels have a cavity for the placement of insulating material. The insulating material is encapsulated in a liquid impervious container thus preventing condensates from infiltrating the insulating material. The isolation of the insulating material from the ambient moist air of the kiln maintains the insulating quality of the insulation normally lost due to exposure to moisture laden air and also aids in preventing the corrosive effect of moist insulation in contact with the metal surfaces.

Abstract: A method of preparing hydrocarbyl-substituted cresols is disclosed. The method comprises heating a mixture of mono- or di-hydrocarbyl-substituted cresols and an alcohol, which is benzyl alcohol or a C.sub.1 -C.sub.10 aliphatic alcohol, at an elevated temperature in the presence of a catalytic amount of alumina. The product contains at least one hydrocarbyl substituent corresponding to the hydrocarbon moiety of the alcohol used in the process. A typical process employs 4,6-di-t-butyl-m-cresol and isopropanol to prepare a product mixture containing a substantial amount of thymol.

Abstract: A process for preparing cresols from di-hydrocarbyl-substituted cresols, wherein the hydrocarbyl groups contain from 3 to 7 carbon atoms, is disclosed. In the process the di-hydrocarbyl-substituted cresol is contacted with a catalyst (e.g. alumina) in the liquid phase at elevated temperatures and pressure. 4,6-di-t-butyl-m-cresol is a typical feedstock.

Abstract: A method of preparing methyl-substituted phenols is disclosed. The method comprises heating a mixture of mono- or di-hydrocarbyl-substituted cresols and methanol at an elevated temperature in the presence of a catalytic amount of magnesium oxide.

Abstract: Alkyl substituted 1,3-dimethylbenzenes are prepared by reacting a mixture of acetone and 1-alkanols over a catalyst, which preferably is alumina, at elevated temperatures and pressures. Preferably, the product contains substantial amounts of penta- and hexaalkylbenzenes.